YM BioSciences granted Orphan Drug Designation for CYT387
JAK1/2 inhibitor currently in Phase II clinical study in myelofibrosis
12-Aug-2010 -
YM BioSciences Inc. announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company's highly-selective JAK1/2 inhibitor, CYT387, for the treatment of myelofibrosis, a chronic debilitating unmet medical ...
bone marrow
food
hematology
+4